Israel’s Therapix Biosciences has developed a unique tablet for sublingual (under the tongue) administration of THC. A clinical trial of this tablet is anticipated to commence early 2017 for treatment of impairments in cognitive functioning, including early stages of Alzheimer’s disease.

http://www.prnewswire.com/news-releases/therapix-biosciences-successfully-completed-the-development-of-a-formulation-for-a-tablet-for-sublingual-administration-of-thc-for-pharmaceutical-use-599311211.html